naftidrofuryl 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1870 31329-57-4

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • naftidrofurile
  • nafronyl oxalate
  • nafronyl
  • naftidrofuryl
  • naphtidrofuryl
  • naftidrofuryl oxalate
  • naftidrofuryl hydrogen oxalate
A drug used in the management of peripheral and cerebral vascular disorders. It is claimed to enhance cellular oxidative capacity and to be a spasmolytic. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1310) It may also be an antagonist at 5HT-2 serotonin receptors.
  • Molecular weight: 383.53
  • Formula: C24H33NO3
  • CLOGP: 5.44
  • LIPINSKI: 1
  • HAC: 4
  • HDO: 0
  • TPSA: 38.77
  • ALOGS: -5.78
  • ROTB: 11

Drug dosage:

DoseUnitRoute
0.60 g O

ADMET properties:

PropertyValueReference
Vd (Volume of distribution) 0.98 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 10.80 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.20 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.35 hours Lombardo F, Berellini G, Obach RS

Approvals:

None

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 57.29 47.71 44 540 304944 34651403
Lactic acidosis 51.69 47.71 20 564 34752 34921595

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Acute kidney injury 82.84 39.34 59 872 519345 79224112
Lactic acidosis 54.73 39.34 23 908 70336 79673121
Hyperkalaemia 52.85 39.34 26 905 114372 79629085

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC C04AX21 CARDIOVASCULAR SYSTEM
PERIPHERAL VASODILATORS
PERIPHERAL VASODILATORS
Other peripheral vasodilators
MeSH PA D002317 Cardiovascular Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018490 Serotonin Agents
MeSH PA D012702 Serotonin Antagonists
MeSH PA D014665 Vasodilator Agents

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Cerebrovascular disease indication 62914000 DOID:6713
Chronic Occlusive Peripheral Arterial Disease indication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.43 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
5-hydroxytryptamine receptor 2A GPCR Ki 6.82 CHEMBL

External reference:

IDSource
D05107 KEGG_DRUG
3200-06-4 SECONDARY_CAS_RN
C0027329 UMLSCUI
CHEBI:91817 CHEBI
CHEMBL1439099 ChEMBL_ID
CHEMBL1620794 ChEMBL_ID
CHEMBL1443491 ChEMBL_ID
DB13588 DRUGBANK_ID
2177 INN_ID
42H8PQ0NMJ UNII
4417 PUBCHEM_CID
7236 RXNORM
003746 NDDF
003776 NDDF
006857 NDDF
006858 NDDF
350627007 SNOMEDCT_US
395807000 SNOMEDCT_US
395992001 SNOMEDCT_US
D009257 MESH_DESCRIPTOR_UI

Pharmaceutical products:

None